Perspective Therapeutics (CATX)
Perspective Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
16.7M
Short interest
settlement 2026-10-15
8.9
Days to cover
+3.4 days vs prior
50.5%
Short share of volume
2026-11-02
1,700
Fails to deliver
settlement 2026-10-13
Mon 9 Nov
Next earnings
estimated date
-$1.6M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CATX is 16,679,713 shares, down 6,126,578 shares over the last month. Over the last 48 readings it ranged from 5,022,843 shares (15 April 2025) to 23,472,935 shares (31 July 2026). At the reported average volume of 1.9M shares a day that is 8.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/catx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 16,679,713 | +0.7% | 1,873,516 | 8.90 |
| 2026-09-30 | 16,570,625 | -27.3% | 3,002,054 | 5.52 |
| 2026-09-15 | 22,806,291 | -2.3% | 1,353,412 | 16.85 |
| 2026-08-31 | 23,352,203 | +1.4% | 987,921 | 23.64 |
| 2026-08-14 | 23,038,136 | -1.9% | 1,264,403 | 18.22 |
| 2026-07-31 | 23,472,935 | +3.0% | 914,970 | 25.65 |
| 2026-07-15 | 22,783,577 | +0.3% | 2,275,008 | 10.01 |
| 2026-06-30 | 22,724,265 | +66.7% | 3,119,657 | 7.28 |
| 2026-06-15 | 13,633,708 | +6.8% | 1,517,321 | 8.99 |
| 2026-05-29 | 12,763,401 | +1.2% | 1,128,371 | 11.31 |
| 2026-05-15 | 12,615,884 | -2.9% | 1,585,811 | 7.96 |
| 2026-04-30 | 12,997,351 | -4.9% | 1,541,167 | 8.43 |
| 2026-04-15 | 13,672,045 | -3.2% | 759,912 | 17.99 |
| 2026-03-31 | 14,123,380 | +39.9% | 1,945,530 | 7.26 |
| 2026-03-13 | 10,094,062 | +4.7% | 1,289,691 | 7.83 |
| 2026-02-27 | 9,644,608 | +0.3% | 2,128,806 | 4.53 |
| 2026-02-13 | 9,610,826 | +0.7% | 4,882,749 | 1.97 |
| 2026-01-30 | 9,540,242 | +16.2% | 9,490,564 | 1.01 |
| 2026-01-15 | 8,211,185 | -3.9% | 1,539,823 | 5.33 |
| 2025-12-31 | 8,542,582 | +0.0% | 1,057,082 | 8.08 |
| 2025-12-15 | 8,541,741 | +19.4% | 1,705,996 | 5.01 |
| 2025-11-28 | 7,152,424 | +6.4% | 1,994,786 | 3.59 |
| 2025-11-14 | 6,720,024 | +2.1% | 2,029,098 | 3.31 |
| 2025-10-31 | 6,582,745 | +1.4% | 1,799,075 | 3.66 |
| 2025-10-15 | 6,492,938 | -4.2% | 1,371,994 | 4.73 |
| 2025-09-30 | 6,776,377 | +1.6% | 822,278 | 8.24 |
| 2025-09-15 | 6,671,693 | +4.7% | 817,331 | 8.16 |
| 2025-08-29 | 6,373,501 | +1.4% | 598,669 | 10.65 |
| 2025-08-15 | 6,285,168 | -3.3% | 670,362 | 9.38 |
| 2025-07-31 | 6,496,317 | +2.4% | 769,260 | 8.44 |
| 2025-07-15 | 6,347,204 | +1.7% | 1,179,926 | 5.38 |
| 2025-06-30 | 6,242,706 | +11.2% | 1,662,123 | 3.76 |
| 2025-06-13 | 5,616,516 | +6.4% | 2,077,510 | 2.70 |
| 2025-05-30 | 5,278,241 | -6.7% | 884,200 | 5.97 |
| 2025-05-15 | 5,654,023 | +7.4% | 590,376 | 9.58 |
| 2025-04-30 | 5,266,566 | +4.8% | 688,368 | 7.65 |
| 2025-04-15 | 5,022,843 | -12.0% | 1,161,618 | 4.32 |
| 2025-03-31 | 5,710,412 | -3.9% | 639,697 | 8.93 |
| 2025-03-14 | 5,939,698 | +0.5% | 518,201 | 11.46 |
| 2025-02-28 | 5,909,500 | +7.8% | 644,244 | 9.17 |
| 2025-02-14 | 5,480,817 | +1.2% | 553,735 | 9.90 |
| 2025-01-31 | 5,417,505 | -29.0% | 1,088,511 | 4.98 |
| 2025-01-15 | 7,633,209 | -14.5% | 1,197,831 | 6.37 |
| 2024-12-31 | 8,931,987 | -9.9% | 1,297,306 | 6.89 |
| 2024-12-13 | 9,912,952 | -5.1% | 1,444,394 | 6.86 |
| 2024-11-29 | 10,445,797 | +26.2% | 4,413,970 | 2.37 |
| 2024-11-15 | 8,277,033 | +3.2% | 907,121 | 9.12 |
| 2024-10-31 | 8,022,108 | +1.8% | 598,624 | 13.40 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CATX volume is 50.5%, down 0.6 points over the last five sessions. Over the last 30 readings it ranged from 23.6% (22 September 2026) to 80.1% (2 October 2026). The latest reading is 6.9 points below the 30-session average of 57.4%, on 1.3M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 632K | 1.3M | 50.5% | 5,194 |
| 2026-10-30 | 504K | 1.1M | 44.2% | 0 |
| 2026-10-29 | 452K | 1.1M | 40.4% | 87,928 |
| 2026-10-28 | 584K | 2.3M | 25.7% | 164,163 |
| 2026-10-27 | 2.4M | 5.8M | 42.4% | 471,596 |
| 2026-10-26 | 3.2M | 6.3M | 51.1% | 354,369 |
| 2026-10-23 | 1.8M | 3.0M | 61.3% | 196,307 |
| 2026-10-22 | 193K | 393K | 49.2% | 0 |
| 2026-10-21 | 350K | 530K | 66.1% | 0 |
| 2026-10-20 | 512K | 769K | 66.6% | 1,834 |
| 2026-10-19 | 241K | 484K | 49.9% | 862 |
| 2026-10-16 | 449K | 852K | 52.8% | 1,951 |
| 2026-10-15 | 284K | 418K | 67.8% | 50 |
| 2026-10-14 | 402K | 507K | 79.2% | 42,421 |
| 2026-10-13 | 415K | 604K | 68.7% | 5,048 |
| 2026-10-12 | 114K | 198K | 57.5% | 0 |
| 2026-10-09 | 144K | 267K | 54.1% | 0 |
| 2026-10-08 | 666K | 920K | 72.4% | 272 |
| 2026-10-07 | 357K | 594K | 60.1% | 14,138 |
| 2026-10-06 | 937K | 1.3M | 69.9% | 161,067 |
| 2026-10-05 | 692K | 2.0M | 34.0% | 3,553 |
| 2026-10-02 | 572K | 714K | 80.1% | 0 |
| 2026-10-01 | 262K | 436K | 60.1% | 0 |
| 2026-09-30 | 279K | 444K | 62.7% | 0 |
| 2026-09-29 | 390K | 512K | 76.2% | 0 |
| 2026-09-28 | 271K | 455K | 59.6% | 589 |
| 2026-09-25 | 446K | 674K | 66.2% | 0 |
| 2026-09-24 | 459K | 704K | 65.2% | 58,751 |
| 2026-09-23 | 1.1M | 1.6M | 64.5% | 83,317 |
| 2026-09-22 | 499K | 2.1M | 23.6% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in CATX is 1,700 shares, down 446 shares over the last settlement date. Over the last 30 readings it ranged from 13 shares (3 June 2026) to 695,239 shares (21 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 1,700 | $2.52 | $4K |
| 2026-10-08 | 2,146 | $2.46 | $5K |
| 2026-09-30 | 160,423 | $2.62 | $420K |
| 2026-09-21 | 695,239 | $2.88 | $2.0M |
| 2026-09-18 | 77,575 | $2.88 | $223K |
| 2026-09-17 | 49,396 | $2.70 | $133K |
| 2026-09-16 | 14,601 | $2.73 | $40K |
| 2026-09-09 | 196 | $3.12 | $612 |
| 2026-08-24 | 1,636 | $3.30 | $5K |
| 2026-08-21 | 8,098 | $3.21 | $26K |
| 2026-08-19 | 25 | $3.21 | $80 |
| 2026-08-17 | 6,669 | $3.20 | $21K |
| 2026-08-14 | 4,045 | $3.10 | $13K |
| 2026-08-13 | 2,764 | $3.26 | $9K |
| 2026-08-11 | 4,687 | $3.00 | $14K |
| 2026-08-07 | 1,422 | $2.97 | $4K |
| 2026-08-05 | 17,821 | $3.00 | $53K |
| 2026-08-04 | 125 | $3.01 | $376 |
| 2026-07-17 | 12,343 | $2.95 | $36K |
| 2026-07-09 | 1,085 | $3.39 | $4K |
| 2026-07-07 | 1,606 | $3.61 | $6K |
| 2026-07-01 | 152,565 | $3.41 | $520K |
| 2026-06-30 | 6,716 | $3.55 | $24K |
| 2026-06-29 | 18 | $3.04 | $55 |
| 2026-06-26 | 4,460 | $3.00 | $13K |
| 2026-06-25 | 7,889 | $3.00 | $24K |
| 2026-06-22 | 31,181 | $2.95 | $92K |
| 2026-06-17 | 1,027 | $2.93 | $3K |
| 2026-06-09 | 212 | $2.93 | $621 |
| 2026-06-03 | 13 | $3.60 | $47 |
Insider trades
SEC Form 4, newest first. JSONInsiders at CATX reported 7 open-market sells worth $1.6M in the last 90 days and no open-market buys. Latest filing: Lantheus Alpha Therapy, LLC (10% owner) on 2026-09-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Lantheus Alpha Therapy, LLC | 10% owner | Sell | 167K | $3.15 | $526K | 11.3M |
| 2026-09-03 | Lantheus Alpha Therapy, LLC | 10% owner | Sell | 81K | $3.11 | $251K | 11.4M |
| 2026-09-02 | Lantheus Alpha Therapy, LLC | 10% owner | Sell | 42K | $3.11 | $131K | 11.5M |
| 2026-09-01 | Lantheus Alpha Therapy, LLC | 10% owner | Sell | 36K | $3.12 | $112K | 11.6M |
| 2026-09-01 | Lantheus Holdings, Inc. | 10% owner | Sell | 36K | $3.12 | $112K | 11.6M |
| 2026-08-31 | Lantheus Alpha Therapy, LLC | 10% owner | Sell | 78K | $3.14 | $246K | 11.6M |
| 2026-08-31 | Lantheus Holdings, Inc. | 10% owner | Sell | 78K | $3.14 | $246K | 11.6M |
| 2025-11-13 | Hunt Jonathan Robert | Chief Accounting Officer | Buy | 11K | $2.03 | $22K | 60K |
| 2025-11-12 | Williamson Robert F III | Director | Buy | 9K | $2.10 | $20K | 10K |
| 2025-03-31 | Woods Lori A | Director | Buy | 23K | $2.13 | $50K | 183K |
| 2025-03-31 | Williamson Robert F III | Director | Buy | 38K | $2.14 | $82K | 109K |
| 2025-03-28 | Graham Juan | Chief Financial Officer | Buy | 33K | $2.25 | $75K | 35K |
| 2025-03-28 | Williamson Robert F III | Director | Buy | 22K | $2.27 | $50K | 71K |
| 2025-03-28 | Spoor Johan M. | Chief Executive Officer | Buy | 22K | $2.24 | $49K | 59K |
| 2025-03-28 | Spoor Johan M. | Chief Executive Officer | Buy | 5K | $2.21 | $10K | 5K |
| 2024-12-04 | Spoor Johan M. | CEO | Buy | 8K | $3.77 | $30K | 36K |
| 2024-12-04 | HENSON HEIDI | Director | Buy | 26K | $3.85 | $100K | 26K |
| 2024-11-25 | Spoor Johan M. | CEO | Buy | 5K | $3.80 | $21K | 5K |
| 2024-11-25 | Spoor Johan M. | CEO | Buy | 15K | $3.78 | $55K | 152K |
| 2024-11-25 | Spoor Johan M. | CEO | Buy | 7K | $3.80 | $25K | 67K |
| 2024-11-25 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 29 | $3.94 | $114 | 36K |
| 2024-11-25 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 400 | $3.55 | $1K | 36K |
| 2024-11-25 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 2K | $3.60 | $9K | 39K |
| 2024-11-25 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 10K | $3.88 | $39K | 49K |
| 2024-11-25 | Williamson Robert F III | Director | Buy | 3K | $3.67 | $10K | 430K |
| 2024-11-25 | Williamson Robert F III | Director | Buy | 4K | $3.62 | $13K | 427K |
| 2024-06-17 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 2K | $9.82 | $18K | 36K |
| 2024-06-14 | Woods Lori A | Director | Buy | 83 | $10.80 | $896 | 160K |
| 2024-06-14 | Woods Lori A | Director | Buy | 5K | $10.90 | $49K | 160K |
| 2024-06-13 | Spoor Johan M. | CEO | Buy | 100K | $1.17 | $117K | 138K |
| 2024-06-03 | Woods Lori A | Director | Buy | 34K | $1.46 | $50K | 1.6M |
| 2024-05-31 | Williamson Robert F III | Director | Buy | 55K | $1.38 | $76K | 424K |
| 2024-05-31 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 12K | $1.40 | $17K | 342K |
| 2024-05-31 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 13K | $1.40 | $18K | 330K |
| 2024-05-29 | Williamson Robert F III | Director | Buy | 19K | $1.34 | $25K | 369K |
| 2024-05-29 | Williamson Robert F III | Director | Buy | 11K | $1.32 | $15K | 350K |
| 2024-04-23 | Austin Mark John | VP Finance/Prin Fin&Acct Offic | Exercise or conversion | 30K | $0.36 | $11K | 84K |
| 2024-03-06 | Lantheus Alpha Therapy, LLC | TenPercentOwner | Buy | 60.4M | $0.95 | $57.4M | 116.8M |
| 2024-01-30 | Williamson Robert F III | Director | Buy | 4K | $0.70 | $2K | 339K |
| 2024-01-30 | Williamson Robert F III | Director | Buy | 19K | $0.71 | $13K | 230K |
| 2024-01-30 | Williamson Robert F III | Director | Buy | 5K | $0.71 | $4K | 235K |
| 2024-01-30 | Williamson Robert F III | Director | Buy | 57K | $0.71 | $41K | 292K |
| 2024-01-30 | Williamson Robert F III | Director | Buy | 43K | $0.72 | $31K | 335K |
| 2024-01-29 | Williamson Robert F III | Director | Buy | 4K | $0.64 | $3K | 190K |
| 2024-01-29 | Williamson Robert F III | Director | Buy | 21K | $0.64 | $14K | 212K |
| 2024-01-26 | Williamson Robert F III | Director | Buy | 15K | $0.61 | $9K | 103K |
| 2024-01-26 | Williamson Robert F III | Director | Buy | 12K | $0.61 | $7K | 88K |
| 2024-01-26 | Williamson Robert F III | Director | Buy | 50K | $0.54 | $27K | 186K |
| 2024-01-26 | Williamson Robert F III | Director | Buy | 25K | $0.55 | $14K | 136K |
| 2024-01-26 | Williamson Robert F III | Director | Buy | 9K | $0.59 | $5K | 111K |
| 2024-01-25 | Williamson Robert F III | Director | Buy | 22K | $0.49 | $11K | 76K |
| 2024-01-24 | Williamson Robert F III | Director | Buy | 30K | $0.49 | $15K | 54K |
| 2024-01-24 | Puhlmann Markus | Chief Medical Officer | Buy | 280K | $0.50 | $140K | 1.4M |
| 2023-12-21 | Williamson Robert F III | Director | Buy | 4K | $0.33 | $1K | 4K |
| 2023-12-19 | Puhlmann Markus | Chief Medical Officer | Buy | 400K | $0.34 | $136K | 1.1M |
| 2023-12-19 | Williamson Robert F III | Director | Buy | 14K | $0.32 | $4K | 24K |
| 2023-12-18 | Puhlmann Markus | Chief Medical Officer | Buy | 60K | $0.26 | $16K | 695K |
| 2023-12-18 | Williamson Robert F III | Director | Buy | 10K | $0.26 | $3K | 10K |
| 2023-12-18 | Hunt Jonathan Robert | Chief Financial Officer | Buy | 125K | $0.26 | $33K | 317K |
| 2023-12-15 | Woods Lori A | Director | Buy | 153K | $0.27 | $41K | 1.5M |
| 2023-12-15 | Puhlmann Markus | Chief Medical Officer | Buy | 135K | $0.27 | $36K | 635K |
| 2023-12-14 | Woods Lori A | Director | Buy | 32K | $0.27 | $9K | 1.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON21 holders report 5% or more of CATX in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is Commodore Capital LP at 9.9% of the class (11,939,753 shares), filed 2026-02-09 for an event on 2026-02-02.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-23 | 13D/Ano. 3 | Lantheus Holdings, Inc.corporation | 8.7M | 7.7% | 2026-09-21 |
| 2026-09-23 | 13D/Ano. 3 | Lantheus Medical Imaging, Inc.corporation | 8.7M | 7.7% | 2026-09-21 |
| 2026-09-23 | 13D/Ano. 3 | Lantheus Alpha Therapy, LLCother entity | 8.7M | 7.7% | 2026-09-21 |
| 2026-08-13 | 13G/Ano. 1 | Israel A. Englanderindividual | 6.3M | 5.5% | 2026-08-07 |
| 2026-08-13 | 13G/Ano. 1 | Millennium Management LLCother entity | 6.3M | 5.5% | 2026-08-07 |
| 2026-08-13 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 6.3M | 5.5% | 2026-08-07 |
| 2026-08-13 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 5.9M | 5.2% | 2026-08-07 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 6.1M | 5.3% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 7.8M | 6.8% | 2026-06-30 |
| 2026-05-12 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 3.0M | 2.6% | 2026-03-31 |
| 2026-03-10 | 13G | Avidity Partners Management LPinvestment adviser, partnership | 6.0M | 5.3% | 2026-02-20 |
| 2026-03-10 | 13G | Avidity Partners Management (GP) LLCother entity | 6.0M | 5.3% | 2026-02-20 |
| 2026-03-10 | 13G | Avidity Capital Partners Fund (GP) LPpartnership | 6.0M | 5.3% | 2026-02-20 |
| 2026-03-10 | 13G | Avidity Capital Partners (GP) LLCother entity | 6.0M | 5.3% | 2026-02-20 |
| 2026-03-10 | 13G | Michael Gregoryparent holding company, individual | 6.0M | 5.3% | 2026-02-20 |
| 2026-03-10 | 13G | Avidity Private Master Fund I LPpartnership | 5.8M | 5.1% | 2026-02-20 |
| 2026-02-09 | 13G | Commodore Capital LPinvestment adviser, partnership | 11.9M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | Commodore Capital Master LPpartnership | 11.9M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | Robert Egen Atkinsonparent holding company, individual | 11.9M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | Michael Kramarzparent holding company, individual | 11.9M | 9.9% | 2026-02-02 |
| 2026-02-06 | 13G | Chen Yuindividual | 7.9M | 6.9% | 2026-02-03 |
| 2026-02-06 | 13G | TCG Crossover GP II, LLCother entity | 4.0M | 3.5% | 2026-02-03 |
| 2026-02-06 | 13G | TCG Crossover Fund II, L.P.partnership | 4.0M | 3.5% | 2026-02-03 |
| 2026-02-06 | 13G | TCG Crossover GP III, LLCother entity | 4.0M | 3.5% | 2026-02-03 |
| 2026-02-06 | 13G | TCG Crossover Fund III, L.P.partnership | 4.0M | 3.5% | 2026-02-03 |
| 2026-02-05 | 13G | Qatar Investment Authorityother entity | 7.1M | 6.2% | 2026-02-04 |
| 2025-12-05 | 13G/Ano. 3 | FMR LLCparent holding company | 312K | 0.4% | 2025-11-28 |
| 2025-12-05 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 312K | 0.4% | 2025-11-28 |
13F holders
Tracked managers holding CATX at their latest 13F. JSON5 of the 30 tracked managers held CATX at their latest 13F, $35.3M in total at quarter-end prices. Millennium Management is the largest at $16.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 4.9M | $16.7M | 0.01% | +865K |
| Citadel Advisors | 2026-06-30 | 3.8M | $13.0M | 0.00% | +239K |
| Two Sigma Investments | 2026-06-30 | 1.6M | $5.3M | 0.00% | +553K |
| Renaissance Technologies | 2026-06-30 | 59K | $202K | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 28K | $95K | 0.00% | +1K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Perspective Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Perspective Therapeutics (CATX), SEC CIK 728387, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-23.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 728387Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CATX is sold short?
16,679,713 shares were held short at the 2026-10-15 settlement, 8.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CATX's daily short volume?
On 2026-11-02, 631,630 of the 1,250,074 CATX shares reported to FINRA were sold short, 50.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CATX have fails to deliver?
The SEC's latest file shows 1,700 CATX shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are CATX insiders buying or selling?
Insiders at CATX reported 7 open-market sells worth $1.6M in the last 90 days and no open-market buys. Latest filing: Lantheus Alpha Therapy, LLC (10% owner) on 2026-09-04.
Who owns 5% or more of CATX?
21 holders report 5% or more of CATX in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is Commodore Capital LP at 9.9% of the class (11,939,753 shares), filed 2026-02-09 for an event on 2026-02-02.
Which tracked 13F managers own CATX?
5 of the 30 tracked 13F managers held CATX shares at their latest filing, $35.3M in all. The largest: Izzy Englander's Millennium Management (4.9M shares, $16.7M), Ken Griffin's Citadel Advisors (3.8M shares, $13.0M), Two Sigma Investments (1.6M shares, $5.3M), Renaissance Technologies (59K shares, $202K), Cliff Asness's AQR Capital Management (28K shares, $95K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.